School of Pharmacy, College of Medicine, National Taiwan University, Taipei 10051, Taiwan.
Bioorg Med Chem. 2010 Jul 1;18(13):4674-86. doi: 10.1016/j.bmc.2010.05.021. Epub 2010 May 12.
A series of new ureidoindolin-2-one derivatives were synthesized and evaluated as inhibitors of receptor tyrosine kinases. Investigation of structure-activity relationships at positions 5, 6, and 7 of the oxindole skeleton led to the identification of 6-ureido-substituted 3-pyrrolemethylidene-2-oxindole derivatives that potently inhibited both the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) families of receptor tyrosine kinases. Several derivatives showed potency against the PDGFR inhibiting both its enzymatic and cellular functions in the single-digit nanomolar range. Among them, compound 35 was a potent inhibitor against tyrosine kinases, including VEGFR and PDGFR families, as well as Aurora kinases. Inhibitor 36 (non-substituted on the pyrrole or phenyl ring) had a moderate pharmacokinetic profile and completely inhibited tumor growth initiated with the myeloid leukemia cell line, MV4-11, in a subcutaneous xenograft model in BALB/c nude mice.
一系列新的脲基吲哚啉-2-酮衍生物被合成并评估为受体酪氨酸激酶抑制剂。对吲哚骨架 5、6 和 7 位的构效关系的研究,确定了 6-脲基取代的 3-吡咯亚甲基-2-氧吲哚衍生物,这些衍生物能够强烈抑制血管内皮生长因子受体 (VEGFR) 和血小板衍生生长因子受体 (PDGFR) 家族的受体酪氨酸激酶。一些衍生物对 PDGFR 具有抑制作用,其抑制作用在单分子数量的纳摩尔范围内对其酶活性和细胞功能均有效。其中,化合物 35 是一种有效的抑制剂,能够抑制包括 VEGFR 和 PDGFR 家族以及 Aurora 激酶在内的酪氨酸激酶。抑制剂 36(吡咯环或苯基环未取代)具有中等的药代动力学特性,在 BALB/c 裸鼠的皮下异种移植模型中,完全抑制了由髓性白血病细胞系 MV4-11 引发的肿瘤生长。